How much funding has Alebund raised?

Alebund has raised $271.0M in total funding, most recently a Private Equity round.

Who are Alebund's investors?

Alebund's investors include 3H Health, Loyal Valley Capital, Morningside Group, Quan Capital, Kingray Capital, YuanBio Venture Capital.

Where is Alebund headquartered?

Alebund is headquartered in Shanghai.

What industry is Alebund in?

Alebund operates in Biotech, Healthcare.

Alebund

Shanghai · Founded 2018 · $271.0M raised

Biotech

Healthcare

Headquarters: Shanghai
Employees: 51–200
Founded: 2018
Business Model: Other

Website: alebund.com
Total Funding: $271.0M
Last Round: $81.5M Private EquityJun 2026
Rounds: 4

About

Alebund Pharmaceuticals is a Shanghai-based clinical-stage biopharmaceutical company founded in 2018 by Gavin Xia and Jin Tian, developing novel therapies for renal diseases including chronic kidney disease, IgA nephropathy, FSGS, and ADPKD. Its pipeline includes 8 product candidates, 2 of which are in commercialization or have completed Phase 3 trials. The company listed on the Hong Kong Stock Exchange (09637.HK) in 2026 and operates manufacturing sites in Yangzhou and Shanghai.

Summary

Alebund is a Biotech company based in Shanghai, founded in 2018. It has raised $271.0M in total across 4 rounds, most recently a $81.5M Private Equity round in Jun 2026. Investors include 3H Health, Loyal Valley Capital and Morningside Group.